SELLAS Life Sciences (SLS) Long-Term Deferred Tax (2011 - 2016)

SELLAS Life Sciences (SLS) has 6 years of Long-Term Deferred Tax data on file, last reported at -$5.7 million in Q4 2016.

• Long-Term Deferred Tax for Q4 2016 came in at -$5.7 million, down 4.49% year-over-year; the trailing twelve-month figure through Dec 2016 was -$5.7 million (down 4.49% YoY), and the FY2016 annual result was -$5.7 million, down 4.49% from the prior year.
• Long-Term Deferred Tax declined to -$5.7 million in Q4 2016 per SLS's latest filing, from -$5.4 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at -$5.1 million in Q1 2012 and troughed at -$5.7 million in Q4 2016.
• A 5-year average of -$5.1 million and a median of -$5.1 million in 2012 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2012 and 2015: Long-Term Deferred Tax changed 0.0% in 2012, then dropped 7.22% in 2015.
• A 5-year view of Long-Term Deferred Tax shows it stood at -$5.1 million in 2012, then changed by 0.0% to -$5.1 million in 2013, then changed by 0.0% to -$5.1 million in 2014, then fell by 7.22% to -$5.4 million in 2015, then slipped by 4.49% to -$5.7 million in 2016.
• Business Quant data shows SLS's Long-Term Deferred Tax at -$5.7 million in Q4 2016, -$5.4 million in Q4 2015, and -$5.1 million in Q3 2015.